Development of stable formulations of pemetrexed

Year 2024, Volume: 28 Issue: 5, 1516 - 1525, 28.06.2025

Pratik Ashwinbhai Vora Rakesh Patel Abhay Dharamsi Devanshu Patel Umang Shah

Abstract

This research has developed an improved lyophilized formulation for Pemetrexed to enhance its stability using various techniques such as amino acids, boric acid, and sugars. The preliminary screening identified sorbitol as the most suitable sugar and L-Arginine as most suitable amino acid due to low degradation rate and minimal change in reconstitution time after one month of storage under accelerated stability conditions. 32 factorial design was employed to optimize the formulation, considering the drug-to-boric acid ratio (X1 factor) and the drug-to-L-Arginine ratio (X2 factor). The Design-Expert® software was utilized to generate optimized formula based on the results of nine batches. The desired responses included the % assay of the lyophilized and reconstituted formulations, reconstitution time, and pH of the composition. The optimized batch exhibited results in-line with the software predictions. Stability testing of the optimized batch under accelerated conditions (for six months revealed no significant differences in the evaluation parameters. Furthermore, the optimized formulation outperformed the marketed formulation. Cell line studies conducted on Pemetrexed API and the formulated dosage form demonstrated enhanced efficacy of the formulation, indicated by a lower IC50 value compared to Pemetrexed API alone. These comprehensive studies confirmed the stability of the prepared dosage form.

Keywords

Amino Acid , Anti-cancer agent , Lyophilized dosage form , Pemetrexed , Stability studies

References

• [1] Brazier Y. What are the different types of tumor? https://www.medicalnewstoday.com/articles/249141.php (accessed on 30 September, 2019).
• [2] Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947-959. https://doi.org/10.1182/blood-2012-04-403733
• [3] Kouroukis T, Baldassarre F, Haynes A, Imrie K, Reece D, Cheung M. Bortezomib in multiple myeloma: Treatment response and survival outcome. Tanta Med J 2017;45(3):129-134. https://doi.org/10.3747/co.21.1798
• [4] Orange Book Database. https://www.accessdata.fda.gov/scripts/cder/ob/_info.cfm?Product_No=001&Appl_No=021602&Appl_type=N (accessed on 02 October, 2019).
• [5] Labogene. The lyophilization process. https://www.labogene.com/The-Lyophilization-Process (accessed on 23 July, 2020).
• [6] Edward T, Dietmar K, Chuan S, Gerald G. N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives. European Patent No. EP0432677, 1990.
• [7] Jens K, Bernd R. Pharmaceutical composition comprising pemetrexed together with monothioglycerol l-cysteine or thioglycolic acid. PCT Patent Publication No. WO200156575, 2001.
• [8] Fan J, Geng J, Chen J, Liu C, Chen X, Lu J. Pharmaceutical composition of pemetrexed disodium. Chinese Patent No. CN102266298, 2011.
• [9] Zhao J, Dai J, Ye D, Li X, Dai Y. Pemetrexed disodium freeze-dried injection and preparation method thereof. Chinese Patent No. CN101411710, 2008.
• [10] Tae-Ho S, Sung-ki S, Mase L. Process for preparing pharmaceutical formulation in the form of antioxidant-free solution for injection containing pemetrexed or its salt. PCT Patent Publication No. WO2012121523, 2012.
• [11] Nagesh P, Philip B. Pharmaceutical compositions containing pemetrexed having extended storage stability. PCT Patent Publication No. WO201215810, 2011.
• [12] Synthon B. Stabilized liquid composition comprising pemetrexed. European Patent No. EP2666463, 2012.
• [13] Dhiraj K, Rajesh K, Mukti Y, Krishanu B. Stable ready-to-use pharmaceutical composition of pemetrexed. PCT Patent Publication No. WO2013144814, 2013.
• [14] Edgar S. Pharmaceutical pemetrexed solution. PCT Patent Publication No. WO2013178214, 2013.
• [15] Dhiraj K, Rajesh K, Mukti Y, Krishanu B. Stable ready-to-use pharmaceutical composition of pemetrexed. PCT Patent Publication No. WO2013179248, 2013.
• [16] Indu B, Manoj P, Subhash G, Harish C, Sanjay J. Stable aqueous compositions of pemetrexed. PCT Patent Publication No. WO2013179310, 2013.
• [17] Chen Q, Li X, Zhao X. Pemetrexed disodium freeze-dried composition and preparation method thereof. Chinese Patent No. CN103494777, 2014.
• [18] Zhang W, Feng J. Pemetrexed disodium freeze-dried powder injection for injection and preparation method thereof. Chinese Patent No. CN103432086, 2013.
• [19] Vimal S, Rafiuddin S, Bhagat P, Akshay C, Shivakumar P. Pemetrexed dipotassium formulations. PCT Patent Publication No. WO201460962, 2013.
• [20] Young P, Myung S, Hong J, Ha C, Nak C. A stabilized pemetrexed formulation. PCT Patent Publication No. WO2014084651, 2013.
• [21] Shrinivas P, Geena M, Dharmaraj R, Rajendra K, Srinivas P, Ravikumar P. Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes. PCT Patent Publication No. WO2014122460, 2014.
• [22] Shin M, Crimson P, Nakhyun C, Ha-Yong C. Stabilized pemetrexed preparation. PCT Patent Publication No. WO2014182093, 2014.
• [23] Sachin S, Amit C, Kumara D, Bhavesh P, Harshal B. Liquid pharmaceutical formulations of pemetrexed. PCT Patent Publication No. WO201592758, 2014. http://dx.doi.org/10.29228/jrp.830
• [24] Yashwanth A, Murthy T, Rao M, Rao U. Formulation design and development of lyophilization cycles for novel formulation of proteasome inhibitor: Bortezomib. World J Pharm Pharm Sci. 2017;6(6):1832-1841. https://doi.org/10.20959/wjpps20176-9420
• [25] Prasanna P, Sandhya P, Geetha P, Anuhya V. Novel method development and validation of Bortezomib in bulk and pharmaceutical dosage form by RP-HPLC. J Drug Deliv Therap. 2019;9(1):17-21. https://doi.org/10.22270/jddt.v9i1.2259
• [26] Chandrasekhar K, Raghuveera HG, Krishnam RK, Nagaraju B. Pharmaceutical formulations comprising Pemetrexed. Indian Patent Application No. 2234/CHENP/2011, 2011.
• [27] Pemetrexed Injection. Indian Pharmacopoeia 2018(3); 2872–2873.